Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human CKD-506 single and multiple ascending dose study with food-effect and IBD proof-of-concept parts
NL-OMON45538Phase 1Active, not recruiting
- Sponsor
- Chong Kun Dang Pharmaceutical
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CKD-506 in inflammatory bowel disease (IBD) and rheumatoid arthritis (RA), sponsored by Chong Kun Dang Pharmaceutical. Started Sep 2016; status: active, not recruiting.
02
Drugs
CKD-506
03
Conditions
inflammatory bowel disease (IBD)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON45538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45538.